Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves

UK company's decision to lay off almost half its workforce, divest Parkinson's therapy Apokyn and shut down U.S. operations stems from "not approvable" letter for Frova last fall for menstrual migraine.